Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.03
AMED's Cash to Debt is ranked lower than
88% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 0.34 vs. AMED: 0.03 )
Ranked among companies with meaningful Cash to Debt only.
AMED' s 10-Year Cash to Debt Range
Min: 0  Med: 0.36 Max: N/A
Current: 0.03
Equity to Asset 0.59
AMED's Equity to Asset is ranked higher than
71% of the 197 Companies
in the Global Medical Care industry.

( Industry Median: 0.43 vs. AMED: 0.59 )
Ranked among companies with meaningful Equity to Asset only.
AMED' s 10-Year Equity to Asset Range
Min: -0.31  Med: 0.55 Max: 1
Current: 0.59
-0.31
1
Interest Coverage 2.93
AMED's Interest Coverage is ranked lower than
75% of the 122 Companies
in the Global Medical Care industry.

( Industry Median: 7.21 vs. AMED: 2.93 )
Ranked among companies with meaningful Interest Coverage only.
AMED' s 10-Year Interest Coverage Range
Min: 1.98  Med: 12.24 Max: 115.64
Current: 2.93
1.98
115.64
F-Score: 3
Z-Score: 4.74
M-Score: -2.17
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -1.20
AMED's Operating margin (%) is ranked lower than
80% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 7.51 vs. AMED: -1.20 )
Ranked among companies with meaningful Operating margin (%) only.
AMED' s 10-Year Operating margin (%) Range
Min: -100.58  Med: 5.01 Max: 15.25
Current: -1.2
-100.58
15.25
Net-margin (%) -0.81
AMED's Net-margin (%) is ranked lower than
72% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 3.29 vs. AMED: -0.81 )
Ranked among companies with meaningful Net-margin (%) only.
AMED' s 10-Year Net-margin (%) Range
Min: -97.66  Med: 3.34 Max: 9.33
Current: -0.81
-97.66
9.33
ROE (%) -2.61
AMED's ROE (%) is ranked lower than
76% of the 192 Companies
in the Global Medical Care industry.

( Industry Median: 8.87 vs. AMED: -2.61 )
Ranked among companies with meaningful ROE (%) only.
AMED' s 10-Year ROE (%) Range
Min: -94.38  Med: 7.59 Max: 24.6
Current: -2.61
-94.38
24.6
ROA (%) -1.44
AMED's ROA (%) is ranked lower than
72% of the 213 Companies
in the Global Medical Care industry.

( Industry Median: 3.19 vs. AMED: -1.44 )
Ranked among companies with meaningful ROA (%) only.
AMED' s 10-Year ROA (%) Range
Min: -73.91  Med: 9.02 Max: 14.03
Current: -1.44
-73.91
14.03
ROC (Joel Greenblatt) (%) -4.84
AMED's ROC (Joel Greenblatt) (%) is ranked lower than
82% of the 211 Companies
in the Global Medical Care industry.

( Industry Median: 16.21 vs. AMED: -4.84 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AMED' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -489.79  Med: 74.77 Max: 393.32
Current: -4.84
-489.79
393.32
Revenue Growth (3Y)(%) -10.50
AMED's Revenue Growth (3Y)(%) is ranked lower than
84% of the 155 Companies
in the Global Medical Care industry.

( Industry Median: 7.90 vs. AMED: -10.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AMED' s 10-Year Revenue Growth (3Y)(%) Range
Min: -26.1  Med: 6.70 Max: 35.1
Current: -10.5
-26.1
35.1
» AMED's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

AMED Guru Trades in Q2 2014

Jim Simons 338,601 sh (+134.03%)
Charles Brandes 165,290 sh (+0.10%)
» More
Q3 2014

AMED Guru Trades in Q3 2014

Paul Tudor Jones 13,000 sh (New)
Steven Cohen 62,400 sh (New)
Jim Simons 259,501 sh (-23.36%)
Charles Brandes 15,810 sh (-90.43%)
» More
Q4 2014

AMED Guru Trades in Q4 2014

Joel Greenblatt 23,349 sh (New)
Paul Tudor Jones 29,819 sh (+129.38%)
Steven Cohen Sold Out
Charles Brandes Sold Out
Jim Simons 209,801 sh (-19.15%)
» More
Q1 2015

AMED Guru Trades in Q1 2015

Joel Greenblatt 39,534 sh (+69.32%)
Paul Tudor Jones 12,578 sh (-57.82%)
Jim Simons 67,601 sh (-67.78%)
» More
» Details

Insider Trades

Latest Guru Trades with AMED

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 28.65
AMED's Forward P/E is ranked lower than
85% of the 96 Companies
in the Global Medical Care industry.

( Industry Median: 19.65 vs. AMED: 28.65 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 3.75
AMED's P/B is ranked lower than
60% of the 188 Companies
in the Global Medical Care industry.

( Industry Median: 2.75 vs. AMED: 3.75 )
Ranked among companies with meaningful P/B only.
AMED' s 10-Year P/B Range
Min: 0.5  Med: 1.94 Max: 3.89
Current: 3.75
0.5
3.89
P/S 1.11
AMED's P/S is ranked higher than
64% of the 211 Companies
in the Global Medical Care industry.

( Industry Median: 1.52 vs. AMED: 1.11 )
Ranked among companies with meaningful P/S only.
AMED' s 10-Year P/S Range
Min: 0.19  Med: 0.78 Max: 2.36
Current: 1.11
0.19
2.36
Current Ratio 0.89
AMED's Current Ratio is ranked lower than
68% of the 199 Companies
in the Global Medical Care industry.

( Industry Median: 1.35 vs. AMED: 0.89 )
Ranked among companies with meaningful Current Ratio only.
AMED' s 10-Year Current Ratio Range
Min: 0.33  Med: 1.00 Max: 2.88
Current: 0.89
0.33
2.88
Quick Ratio 0.89
AMED's Quick Ratio is ranked lower than
64% of the 199 Companies
in the Global Medical Care industry.

( Industry Median: 1.20 vs. AMED: 0.89 )
Ranked among companies with meaningful Quick Ratio only.
AMED' s 10-Year Quick Ratio Range
Min: 0.31  Med: 0.99 Max: 2.85
Current: 0.89
0.31
2.85
Days Sales Outstanding 33.45
AMED's Days Sales Outstanding is ranked higher than
72% of the 184 Companies
in the Global Medical Care industry.

( Industry Median: 46.89 vs. AMED: 33.45 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMED' s 10-Year Days Sales Outstanding Range
Min: 27.44  Med: 42.86 Max: 78.46
Current: 33.45
27.44
78.46

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 10.69
AMED's Price/Tangible Book is ranked lower than
84% of the 139 Companies
in the Global Medical Care industry.

( Industry Median: 4.01 vs. AMED: 10.69 )
Ranked among companies with meaningful Price/Tangible Book only.
AMED' s 10-Year Price/Tangible Book Range
Min: 0.35  Med: 4.15 Max: 2380
Current: 10.69
0.35
2380
Price/Projected FCF 1.40
AMED's Price/Projected FCF is ranked higher than
57% of the 94 Companies
in the Global Medical Care industry.

( Industry Median: 1.51 vs. AMED: 1.40 )
Ranked among companies with meaningful Price/Projected FCF only.
AMED' s 10-Year Price/Projected FCF Range
Min: 0.16  Med: 0.94 Max: 12.84
Current: 1.4
0.16
12.84
Price/Median PS Value 1.42
AMED's Price/Median PS Value is ranked lower than
65% of the 193 Companies
in the Global Medical Care industry.

( Industry Median: 1.14 vs. AMED: 1.42 )
Ranked among companies with meaningful Price/Median PS Value only.
AMED' s 10-Year Price/Median PS Value Range
Min: 0.13  Med: 0.64 Max: 2.66
Current: 1.42
0.13
2.66
Price/Peter Lynch Fair Value 0.56
AMED's Price/Peter Lynch Fair Value is ranked lower than
560% of the 50 Companies
in the Global Medical Care industry.

( Industry Median: 2.31 vs. AMED: 0.56 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
AMED' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.21  Med: 0.72 Max: 3.24
Current: 0.56
0.21
3.24
Earnings Yield (Greenblatt) (%) -0.38
AMED's Earnings Yield (Greenblatt) (%) is ranked lower than
78% of the 202 Companies
in the Global Medical Care industry.

( Industry Median: 3.80 vs. AMED: -0.38 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AMED' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -0.38  Med: 9.40 Max: 33.7
Current: -0.38
-0.38
33.7
Forward Rate of Return (Yacktman) (%) 36.73
AMED's Forward Rate of Return (Yacktman) (%) is ranked higher than
95% of the 101 Companies
in the Global Medical Care industry.

( Industry Median: 10.88 vs. AMED: 36.73 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AMED' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 1.5  Med: 40.60 Max: 104.4
Current: 36.73
1.5
104.4

Business Description

Industry: Health Care Providers » Medical Care
Compare:CHE, FMS, DVA, FSNUY, BDUUF » details
Traded in other countries:ADY.Germany,
Amedisys Inc was originally incorporated in Louisiana in 1982. Its operations were transferred to a Delaware corporation, which was incorporated in 1994; and became a publicly traded company in August of that year. The Company is a provider of low-cost home health services to the chronic, co-morbid, aging American population. The operations involve servicing patients through its two reportable business segments: home health and hospice. The home health segment delivers services in the homes of individuals who may be recovering from an illness, injury or surgery. Its hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. Individuals with a terminal illness such as heart disease, pulmonary disease, dementia, Alzheimers, HIV/AIDS or cancer may be eligible for hospice care. The Company operates 41 home health care centers and five hospice care centers with care centers servicing the same markets, sold 19 home health care centers and one hospice care center and closed 10 home health care centers. The Companys operations are regulated by Federal, state and local authorities.
» More Articles for AMED

Headlines

Articles On GuruFocus.com
comment on AMED Jun 20 2012 
well undervalued, st Jan 24 2012 
“Powerball” Ideas - Home Healthcare Companies: AFAM, GTIV, LHCG, AMED Jan 05 2012 
AMED: Investment Opportunity When the Price Hits an 8-Year Low Dec 27 2011 
Almost Family: The Magic Formula Stock is getting cheaper and cheaper Dec 11 2011 
guru bargain Oct 05 2011 
Magic Formula Stock: Amedisys (AMED) Aug 05 2011 
Home Healthcare: Heavily Shorted long Opportunity May 30 2011 
Amedisys Inc (AMED) CFO Dale E Redman buys 1,000 Shares Aug 25 2010 
Amedisys Inc Reports Operating Results (10-Q) Aug 09 2010 

More From Other Websites
Coverage initiated on Amedisys by Mizuho Jul 01 2015
Almost Family (AFAM) Falls: Stock Goes Down 9.4% - Tale of the Tape Jun 24 2015
Amedisys (AMED) Continues to Rally: Add to Your Portfolio? - Analyst Blog Jun 22 2015
AMEDISYS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 05 2015
Amedisys, Inc. Investors Encouraged to Contact Securities Law Firm about Investigation into... Jun 01 2015
Preliminary Transcript of AMED presentation 1-Jun-15 12:00pm GMT Jun 01 2015
Edited Transcript of AMED presentation 1-Jun-15 12:00pm GMT Jun 01 2015
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amedisys, Inc. -... May 29 2015
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amedisys, Inc. May 29 2015
AMEDISYS INC Files SEC form 8-K, Other Events May 28 2015
2 Health Care and 2 Tech Stocks Set to Go Higher on Continued Momentum May 28 2015
Amedisys to Present at the Jefferies 2015 Healthcare Conference May 28 2015
Amedisys (AMED) Worth Watching: Stock Moves 8.7% Higher - Tale of the Tape May 28 2015
Why You Shouldn't Bet Against Amedisys (AMED) Stock - Tale of the Tape May 21 2015
AMEDISYS INC Files SEC form 8-K, Regulation FD Disclosure May 12 2015
Increased Earnings Estimates Seen for Amedisys (AMED): Can It Move Higher? - Tale of the Tape May 07 2015
Amedisys to Present at the Bank of America Merrill Lynch Health Care Conference May 06 2015
Amedisys to Present at the Bank of America Merrill Lynch Health Care Conference May 06 2015
Vote of confidence in Amedisys May 06 2015
Zacks Rank #1 Additions for Tuesday - Tale of the Tape May 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK